Spyre Therapeutics, Inc. (SYRE) — SEC Filings
Spyre Therapeutics, Inc. (SYRE) — 50 SEC filings. Latest: 8-K (May 5, 2026). Includes 15 8-K, 14 SC 13G/A, 6 10-Q.
View Spyre Therapeutics, Inc. on SEC EDGAR
Overview
Spyre Therapeutics, Inc. (SYRE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 13, 2026: On April 13, 2026, Spyre Therapeutics, Inc. filed an 8-K report detailing events under Regulation FD Disclosure and Other Events. The filing includes various exhibits, such as financial statements and data releases, but does not specify any new material agreements or financial figures.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 48 neutral, 2 mixed. The dominant filing sentiment for Spyre Therapeutics, Inc. is neutral.
Filing Type Overview
Spyre Therapeutics, Inc. (SYRE) has filed 15 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 10-K/A, 14 SC 13G/A, 4 SC 13G, 1 8-K/A, 1 S-1, 3 S-1/A with the SEC between Feb 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of SYRE's 29 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$11.183M |
| EPS | N/A |
| Debt-to-Equity | 0.11 |
| Cash Position | $64.897M |
| Operating Margin | N/A |
| Total Assets | $504.604M |
| Total Debt | $49.504M |
Key Executives
- Cameron Turtle
- Scott Burrows
- Jeffrey M. Goldberg
- Jonathan Alspaugh
- Dr. Anthony Quinn
- Jim Kastenmayer
Industry Context
Spyre Therapeutics operates in the biotechnology sector, characterized by high R&D investment, long development cycles, and significant regulatory hurdles. The competitive landscape is intense, with numerous companies vying for breakthroughs in therapeutic areas. Success often hinges on clinical trial outcomes and the ability to secure substantial funding to advance drug candidates through development and commercialization.
Top Tags
Spyre Therapeutics (7) · SEC Filing (6) · 10-Q (5) · corporate-action (5) · financials (5) · Pharmaceuticals (4) · name-change (3) · material-agreement (3) · corporate-governance (3) · SYRE (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $11.183M | Decreased from $69.028M in Q3 2024, a 83.8% improvement. |
| Net Loss (YTD 2025) | $92.673M | Decreased from $151.722M in YTD 2024, a 38.9% improvement. |
| R&D Expenses (Q3 2025) | $45.247M | Increased from $44.744M in Q3 2024, a 1.1% increase. |
| R&D Expenses (YTD 2025) | $127.015M | Increased from $112.308M in YTD 2024, a 13.1% increase. |
| Gain on CVR Liability (YTD 2025) | $42.199M | Significant positive impact compared to a $19.630M loss in YTD 2024. |
| Gain on Asset Sale (YTD 2025) | $10.000M | New income source not present in YTD 2024. |
| Cash and Cash Equivalents | $64.897M | Decreased from $89.423M at Dec 31, 2024, a 27.4% decrease. |
| Net Cash Used in Operations (YTD 2025) | $124.674M | Increased from $120.211M in YTD 2024, a 3.7% increase in cash burn. |
| Common Shares Outstanding | 77,592,130 | As of October 29, 2025, indicating potential dilution. |
| SEC File Number | 001-37722 | Identifies the company's filing with the SEC |
| IRS Employer Identification No. | 46-4312787 | Company's tax identification number |
| Revenue | $0 | No revenue reported for Q2 2025 or YTD 2025, highlighting pre-commercial stage. |
| Net Loss (Q2 2025) | $33.0M | Represents a 25% improvement from $44.0M net loss in Q2 2024. |
| G&A Expenses (YTD 2025) | $0 | Dramatic reduction from $44.0M in YTD 2024, suggesting cost reclassification or efficiency. |
| Reporting Period | 2025 Q1 | First quarter of 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Spyre Therapeutics, Inc. (SYRE)?
Spyre Therapeutics, Inc. has 50 recent SEC filings from Feb 2024 to May 2026, including 15 8-K, 14 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SYRE filings?
Across 50 filings, the sentiment breakdown is: 48 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Spyre Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Spyre Therapeutics, Inc. (SYRE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Spyre Therapeutics, Inc.?
Key financial highlights from Spyre Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SYRE?
The investment thesis for SYRE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Spyre Therapeutics, Inc.?
Key executives identified across Spyre Therapeutics, Inc.'s filings include Cameron Turtle, Scott Burrows, Jeffrey M. Goldberg, Jonathan Alspaugh, Dr. Anthony Quinn and 1 others.
What are the main risk factors for Spyre Therapeutics, Inc. stock?
Of SYRE's 29 assessed filings, 1 were flagged high-risk, 16 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Spyre Therapeutics, Inc.?
Forward guidance and predictions for Spyre Therapeutics, Inc. are extracted from SEC filings as they are enriched.